Several other research firms also recently issued reports on NEO. Zacks Investment Research downgraded NeoGenomics from a hold rating to a sell rating in a report on Thursday, October 5th. BidaskClub downgraded NeoGenomics from a strong-buy rating to a buy rating in a report on Wednesday, September 13th. Gabelli started coverage on NeoGenomics in a research note on Thursday, August 24th. They set a buy rating and a $9.00 target price for the company. Finally, BTIG Research cut NeoGenomics from a buy rating to a neutral rating in a research note on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and an average price target of $10.33.
NeoGenomics (NASDAQ:NEO) opened at $8.59 on Thursday. The company has a current ratio of 2.37, a quick ratio of 2.21 and a debt-to-equity ratio of 0.60. NeoGenomics has a 12-month low of $7.12 and a 12-month high of $11.63. The firm has a market capitalization of $681.94, a P/E ratio of 171.80, a P/E/G ratio of 6.78 and a beta of 0.84.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.01. The firm had revenue of $63.05 million for the quarter, compared to analyst estimates of $63.11 million. NeoGenomics had a positive return on equity of 3.98% and a negative net margin of 4.78%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 earnings per share. equities analysts predict that NeoGenomics will post 0.06 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Janney Montgomery Scott Reaffirms Buy Rating for NeoGenomics, Inc. (NEO)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/13/neogenomics-inc-neo-given-buy-rating-at-janney-montgomery-scott.html.
Several hedge funds have recently modified their holdings of NEO. Cambridge Investment Research Advisors Inc. grew its holdings in shares of NeoGenomics by 7.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,600 shares of the medical research company’s stock worth $107,000 after acquiring an additional 1,000 shares during the period. Wrapmanager Inc. acquired a new stake in shares of NeoGenomics in the 2nd quarter worth approximately $109,000. KCG Holdings Inc. acquired a new stake in NeoGenomics during the 1st quarter valued at $118,000. OLD National Bancorp IN acquired a new stake in NeoGenomics during the 2nd quarter valued at $141,000. Finally, Empirical Finance LLC acquired a new stake in NeoGenomics during the 3rd quarter valued at $159,000. 80.35% of the stock is owned by institutional investors and hedge funds.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.